Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	451.8	131.55	141.79	118.32
Short-Term Investments	608.09	598.64	378.86	277.14
Cash & Short-Term Investments	1,060	730.19	520.65	395.46
Cash Growth	106.47%	40.24%	31.66%	-
Other Current Assets	13.91	11.17	9.06	2.95
Total Current Assets	1,074	741.36	529.71	398.41
Net Property, Plant & Equipment	12.99	14.38	13.32	2.59
Long-Term Investments	198.35	172.73	210.42	-
Other Long-Term Assets	8.52	8.67	0.5	0.4
Total Assets	1,294	937.13	753.95	401.4
Accounts Payable	1.24	1.22	1.07	2.14
Accrued Expenses	28.58	23.18	24.26	17.31
Current Portion of Leases	3.14	3.5	3.23	1.1
Total Current Liabilities	32.95	27.91	28.56	20.56
Long-Term Leases	4.91	5.35	8.6	0.93
Total Long-Term Liabilities	4.91	5.35	8.6	0.93
Total Liabilities	37.86	33.25	37.16	21.49
Common Stock	0	0	0	-
Additional Paid-in Capital	1,892	1,465	1,022	503.35
Accumulated Other Comprehensive Income	-0.75	1.08	0.92	0.33
Retained Earnings	-635.87	-561.76	-305.92	-123.77
Shareholders' Equity	1,256	903.88	716.79	379.91
Total Liabilities & Equity	1,294	937.13	753.95	401.4
Total Debt	8.05	8.85	11.83	2.03
Net Cash (Debt)	1,052	721.34	508.82	393.43
Net Cash Growth	45.82%	41.77%	29.33%	-
Net Cash Per Share	16.55	11.89	9.22	15.73
Book Value	1,256	903.88	716.79	379.91
Book Value Per Share	19.76	14.89	12.99	15.19
Tangible Book Value	1,256	903.88	716.79	379.91
Tangible Book Value Per Share	19.76	14.89	12.99	15.19

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q